Eton (ETON) Director Paul Maier Exercises Options, Sells 50,000 Shares

What Happened
Paul Maier, a director of Eton Pharmaceuticals (ETON), exercised 50,000 stock options on 2026-08-28 at $3.78 per share (total exercise cost $189,000) and immediately sold 50,000 shares in the open market the same day. The sales were executed in multiple trades at weighted-average prices reported as $58.64 (36,387 shares), $60.21 (13,485 shares) and $61.77 (128 shares), generating aggregate gross proceeds of approximately $2,953,573. Transaction codes: M = option exercise/conversion; S = open-market sale.

Key Details

• Transaction date: 2026-08-28 (filed the same day). Filing not reported as late.
• Exercise: 50,000 shares at $3.78 each — total paid $189,000.
• Sales: total 50,000 shares sold in multiple trades for aggregate proceeds ≈ $2,953,573 (breakdown: 36,387 @ $58.64 = $2,133,734; 13,485 @ $60.21 = $811,932; 128 @ $61.77 = $7,907).
• Price notes: reported sale prices are weighted averages; actual trade prices ranged $58.50–$58.97, $60.00–$61.00, and $61.10–$61.98 per the filing footnotes.
• Vesting note: the option shares vested monthly (48 equal installments) from grant date 02-07-2022 (footnote).
• Shares owned after transaction: not specified in the Form 4 provided.
• Filing remark: the reporting person authorized a designated filer to submit this Form 4 on their behalf.

Context

• This is effectively a cashless exercise and sale: Maier exercised options by paying the exercise price and sold the resulting shares the same day, converting option value to cash. Such transactions are common for insiders exercising vested options and do not by themselves indicate future company performance.